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Abstract: Allergen immunotherapy (AIT) is the only curative treatment for allergic diseases. It induces
immune tolerance together with the reduction of the symptoms of asthma and allergic rhinitis patients.
The common routes for the application of AIT for respiratory allergens are subcutaneous immunotherapy
(SCIT) and sublingual immunotherapy (SLIT). SCIT improves the symptoms of asthma and rhinitis and
increase the quality of life.
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Allergen immunotherapy (AIT) is the only curative treatment for allergic diseases. It 
induces immune tolerance together with the reduction of the symptoms of asthma and 
allergic rhinitis patients. The common routes for the application of AIT for respiratory 
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(SLIT). SCIT improves the symptoms of asthma and rhinitis and increase the quality of 
life. SLIT is a non-invasive, well-tolerated and efficient treatment for respiratory allergies.1 
In this issue of Allergy, Heeringa et al. report that sublingual immunotherapy induces 
IgG2 and IgG4 B-cell memory. Although, it was shown that AIT has long lasting beneficial 
effects, there is still relatively little known on how this affects the B cell memory. This 
question was studied longitudinally before, during and after SLIT for grass pollen allergy 
in moderate to severe seasonal allergic rhinitis.2 
Despite its relative success, AIT faces several challenges, including worldwide 
standardization, limitations in efficacy, sometimes severe side effects, low patient 
adherence, and high costs due to the long duration (3 to 5 years) of treatment. Various 
approaches are being pursued to answer all of the above challenges. Grass pollen SLIT 
has been recommended in this study as a pre- and co-seasonal course starting 4 months 
prior to the hay fever season, confirmed by meta-analyses as clinically effective. Patients 
are exposed to grass pollens during the spring season, in this study patients received a 
4-month pre-seasonal treatment regimen that would avoid the risk of adding to excessive 
and unpredictable allergen loads during the season.3 Based on analysis of symptom 
scores, this approach was highly effective. Prolonged treatment (duration >12 months) is 
known to have beneficial effects on symptom and medication scores. The fact that some 
immunological effects were delayed, only occurring after the second or third treatment 
year as observed for serum ragweed pollen (RGP)-specific IgG2 levels, or continuing to 
rise after consecutive treatment as for serum RGP-specific IgG4 levels, supports these 
findings. It was demonstrated that SLIT for grass pollen allergy not only has long-term 
beneficial clinical effects, but also results in sustained systemic effects on the immune 
system. SLIT induced a rapid and prolonged increase in RGP-specific serum IgG4 
accompanied by an increase in the frequency of peripheral blood IgG4+ memory B cells. 
Furthermore, repeated courses of SLIT resulted in a similar increase in RGP-specific 
IgG2 in serum corresponding with increased frequency of IgG2+ memory B cells in the 
blood. However, it must be noted that the increases of IgG2+ and IgG4+ circulating B cell 
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The effector mechanisms that can be triggered by antibodies due to complement 
activation, antibody-dependent cellular cytotoxicity, immune complex formation differ 
between the different immunoglobulin subclasses. IgG1 and IgG3 can efficiently trigger 
the classical route of complement activation, while IgG2 and IgG4 do so less efficiently or 
only under certain conditions for IgG2.3 IgG2 and IgG4 that show reduced affinity to a 
number of FcγR. Additionally, IgG2 and IgG4 have very limited ability to elicit antibody-
dependent cell-mediated cytotoxicity.4
The effect of AIT on IgG2 production has not been extensively reported and IgG2 was not 
measured on most of the studies. In this study, Heeringa et al. demonstrated that SLIT 
increased RGP-specific IgG2 after three consecutive courses. This suggests that 
repeated or high dose exposure to RGP from SLIT is required to enhance RGP- specific 
IgG2 beyond levels that are generated in response to annual RGP exposure during the 
pollen season. Furthermore, sublingual administration of RGP may have preferentially 
induced an IgG2 response not seen from environmental exposure through the airway. 
However, the immune mechanisms by which allergen-specific IgG2 may contribute to the 
benefits of immunotherapy remain unclear. IgG2 has been shown to inhibit histamine 
release from basophils by activating FcγRIIb and may reduce allergic symptoms by this 
mechanism. In a similar manner to IgG4, IgG2 may also bind allergen and prevent 
effector cell degranulation by masking IgE epitopes.
Previously, both SCIT7 or SLIT9, have been demonstrated to result in increased allergen-
specific IgG4 serum levels. Increased allergen-specific IgG4 has been postulated as one 
of the explanations for the beneficial effects of immunotherapy and has been observed as 
a natural effect in bee-keepers exposed to bee-venom for prolonged periods, yet the 
exact desensitizing effect of specific IgG4 in immunotherapy remains unclear. Allergen-
specific IgG4 can competitively inhibit IgE from binding to allergens and may 
subsequently reduce allergic responses by preventing FcεR-mediated activation of 
granulocytes.9
In contrast to IgG2, there are several features of IgG4 that may contribute to its non-
inflammatory role. The two arms of IgG4 have the ability to separate and repair by means 
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are functionally monomeric. Furthermore, IgG4 is capable of inhibiting immune-complex 
formation by other isotypes, giving this isotype anti-inflammatory characteristics.5-6
Plasma cells are the cell that produce IgG2 and IgG4 antibodies but the majority of IgG-
producing plasma cells are residing in the bone marrow. For this reason, the authors 
focused primarily on memory B cells, which are abundantly present in the blood due to 
their circulatory nature. These cells have the capacity to quickly differentiate into plasma 
cells in response to recall antigen exposure. 
It is highly possible that the decrease in the IgE/IgG4 ratio during AIT is influenced by the 
skewing of the T cell population from allergen-specific TH2 to Treg cells as well as by 
increases in the number of Breg cells. IL-10, which is produced by both Tregs and Bregs, 
is a potent suppressor of both total and allergen-specific IgE while it simultaneously 
increases IgG4 production.7-8 (Figure 1) In parallel with previous studies, it was also 
shown here that proliferation of Tregs from patients after SLIT was increased in response 
to in vitro stimulation with RGP and increased IL-10 production induces Ig class switching 
of allergen-specific B cells to IgG4.9 B regulatory cells (Breg) and monocyte-derived 
macrophages may also be a substitute source of IL-10 in in vitro studies, further 
enhancing IgG4 class switching in response to RGP.
Figure 1. Mechanisms of AIT.
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